Los puntos clave no están disponibles para este artículo en este momento.
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of a three-part series focusing on treatment delivery for non-metastatic biochemical recurrence (BCR) after primary radical prostatectomy (RP). Please refer to Part I for discussion of treatment decision-making and Part III for discussion of evaluation and management of recurrence after radiotherapy (RT) and focal therapy, regional recurrence, and oligometastasis.
Building similarity graph...
Analyzing shared references across papers
Loading...
Morgan et al. (Thu,) studied this question.
synapsesocial.com/papers/68e76cf5b6db6435876e294e — DOI: https://doi.org/10.1097/ju.0000000000003891
Todd M. Morgan
University of Michigan
Stephen A. Boorjian
Mayo Clinic
Mark K. Buyyounouski
Palo Alto University
The Journal of Urology
Harvard University
Stanford University
University of Washington
Building similarity graph...
Analyzing shared references across papers
Loading...
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: